Pharma found its way into sports

If you’ve spent any Sunday this fall watching an NFL broadcast, you may have noticed a shift in the advertising landscape. Alongside the team logos between third-down stops and touchdown drives were cancer screening messages from Novartis, extending beyond national broadcasts into local stadiums across six NFL franchises. Meanwhile, if we look to Major League Baseball, AbbVie has established itself as MLB’s first official pharmaceutical partner, while also bringing its brain health awareness campaigns to the PGA Tour.

These partnerships represent a meaningful change for the pharmaceutical industry that, for decades, has approached sporting events only by purchasing television advertising during commercial breaks. Pharmaceutical companies now want to reach fans beyond traditional TV spots by becoming part of the sporting experience itself, building relationships with leagues, athletes, and audiences in ways that would have been unusual a decade ago.

The appeal of sports to the pharmaceutical industry is backed by numbers. Sporting events accounted for 96 of the 100 most-watched U.S. television broadcasts in 2025. That momentum continued into 2026, with NFL games averaging 18.8 million viewers through the first five weeks of the season, the highest average at this point in a season on record. At a time when audiences are increasingly fragmented across platforms, it’s rare to have such a large captive audience, explaining why brands are looking to establish a presence in professional sports.

RETHINK THE PARTNERSHIP APPROACH

As healthcare digital advertising spending continues to grow and the FDA takes a closer look at direct-to-consumer pharmaceutical marketing, companies are reassessing how they invest their advertising dollars. Beyond the audience size, the growth of women’s sports and greater openness among athletes about their mental and physical health have created opportunities for conversations that extend well beyond competition.

Yet while the industry’s growing presence in sports is encouraging, I worry that some pharmaceutical companies are approaching these partnerships with the same thinking that has long shaped traditional advertising—securing the audience first, then figuring out what to say.

Having spent much of my career in healthcare marketing, I’ve seen how easily a promising partnership can become an exercise in visibility rather than a strategy grounded in patients’ needs. Let’s say a company signs a recognizable athlete. Often, it’s not until after negotiating league sponsorship rights or investing in a high-profile activation that the company begins asking how the arrangement supports its broader business objectives. By that point, the investment has been made, and the pressure to justify it can become more important than determining whether it was the right decision.

AN OPPORTUNITY REQUIRING AUTHENTICITY

Sports organizations and athletes have a reliable “in” with communities that healthcare companies often struggle to reach through conventional advertising. These companies have an opportunity to address health topics that patients are often reluctant to discuss by harnessing the dedicated fan base loyalty and athlete credibility. But without a clear understanding of the healthcare challenges companies are trying to address, these partnerships risk becoming just another advertising opportunity, rather than a campaign built around the outcomes they hope to achieve.

Healthcare requires a different level of participation from athletes and spokespeople compared to typical consumer product endorsements. These campaigns often involve a sensitive diagnosis or personal medical decision. That requires a level of authenticity and vulnerability that can’t be manufactured through the usual advertising tactics. An athlete’s genuine experience with a health issue is much more likely to resonate than one where a recognizable name is just attached to a generic message.

HOW TO MEASURE SUCCESS

The advertising industry needs to change how it measures success for a worthwhile shift to occur. Metrics such as impressions, media coverage, brand awareness, and social engagement are standard for measuring campaign success. While measuring the reach is important, these numbers don’t reveal much, if anything, about whether a campaign has actually influenced health-related decisions. It shouldn’t be assumed that a partnership has improved access to care or encouraged patients to take action just because of these noted numbers attached to it.

Companies should be thinking from the start about how to assess and measure whether audiences sought additional information, discussed screening with a healthcare professional, or took steps toward scheduling an appointment. Not every outcome can be directly attributed to a sponsorship, but establishing those objectives before making an investment provides a more significant basis to evaluate its success.

Pharma has already demonstrated that it can buy its way into some of the biggest stages in professional sports. Whether it can turn that visibility into something valuable for patients will determine if these partnerships become a lasting part of healthcare marketing or simply another expensive way to compete for attention.

Ed Mitzen is the founder of Fingerpaint Group and The Business For Good Foundation.

内容来自 Fast Company,版权归原作者所有。

阅读原文 ↗

把喜欢的内容,留在你的新标签页。

打开我的订阅